Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12741108 | 0.82 | TDP1 (0.48) | EPHX1ALDH1A1TSHRTDP1 | |
| SCHEMBL4730960 | 0.80 | EPHX1 (0.41) | EPHX1ALDH1A1TSHRTET2RECQL | |
| SCHEMBL15033686 | 0.78 | EPHX1 (0.40) | EPHX1TSHRTET2RECQLTDP1 | |
| SCHEMBL12707471 | 0.77 | EPHX1 (0.45) | EPHX1TSHRTET2TDP1 | |
| SCHEMBL22680370 | 0.76 | EPHX1 (0.39) | EPHX1TSHRTET2RECQLTDP1 | |
| SCHEMBL15614667 | 0.76 | EPHX1 (0.39) | EPHX1ALDH1A1TSHRTET2RECQL | |
| SCHEMBL20863002 | 0.76 | NPSR1 (0.36) | ALDH1A1TSHRRECQL | |
| SCHEMBL14930611 | 0.76 | RECQL (0.41) | ALDH1A1TSHRTET2RECQL | |
| SCHEMBL12741104 | 0.75 | KDM4E (0.40) | EPHX1ALDH1A1TSHR | |
| SCHEMBL28649387 | 0.74 | EPHX1 (0.38) | EPHX1TSHRTET2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
| US-20210130302-A1 | Antiviral Pyrazolopyridinone Compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC | 2021-05-06 | — | — | US | disclosed |
| US-9669027-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | EPHX1 1488/4885ALDH1A1 704/4885TSHR 4320/4885 |
| US-20160038483-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | EPHX1 1488/4885ALDH1A1 704/4885TSHR 4320/4885 |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | ZC3HAV1, TYMP, ZC3HAV1L | EPHX1 2121/4885ALDH1A1 1776/4885TSHR 4170/4885 |
| US-20210130302-A1 | Antiviral Pyrazolopyridinone Compounds | ZC3HAV1, TYMP, ZC3HAV1L | EPHX1 2121/4885ALDH1A1 1776/4885TSHR 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.